Abstract
Clofarabine is a second-generation purine nucleoside analog and has significant anti-leukemic activity as a single agent. It is approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children. Combinations of clofarabine with purine nucleoside analogs or DNA-damaging agents have been investigated utilizing synergistic effects and now tested in a number of studies including a frontline study. In this article, we review the development of clofarabine, rationale and history of combination regimens, and their potential roles and toxicities in the treatment of pediatric ALL that are important to treating clinicians.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 417-422 |
| Number of pages | 6 |
| Journal | Pediatric Blood and Cancer |
| Volume | 59 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2012 |
Fingerprint
Keywords
- ALL
- Clofarabine
- New agent
- Relapse
ASJC Scopus subject areas
- Oncology
- Pediatrics, Perinatology, and Child Health
- Hematology
Cite this
Clofarabine in pediatric acute leukemia : Current findings and issues. / Hijiya, Nobuko; Barry, Elly; Arceci, Robert J.
In: Pediatric Blood and Cancer, Vol. 59, No. 3, 09.2012, p. 417-422.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clofarabine in pediatric acute leukemia
T2 - Current findings and issues
AU - Hijiya, Nobuko
AU - Barry, Elly
AU - Arceci, Robert J.
PY - 2012/9
Y1 - 2012/9
N2 - Clofarabine is a second-generation purine nucleoside analog and has significant anti-leukemic activity as a single agent. It is approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children. Combinations of clofarabine with purine nucleoside analogs or DNA-damaging agents have been investigated utilizing synergistic effects and now tested in a number of studies including a frontline study. In this article, we review the development of clofarabine, rationale and history of combination regimens, and their potential roles and toxicities in the treatment of pediatric ALL that are important to treating clinicians.
AB - Clofarabine is a second-generation purine nucleoside analog and has significant anti-leukemic activity as a single agent. It is approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children. Combinations of clofarabine with purine nucleoside analogs or DNA-damaging agents have been investigated utilizing synergistic effects and now tested in a number of studies including a frontline study. In this article, we review the development of clofarabine, rationale and history of combination regimens, and their potential roles and toxicities in the treatment of pediatric ALL that are important to treating clinicians.
KW - ALL
KW - Clofarabine
KW - New agent
KW - Relapse
UR - http://www.scopus.com/inward/record.url?scp=84861726534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861726534&partnerID=8YFLogxK
U2 - 10.1002/pbc.24112
DO - 10.1002/pbc.24112
M3 - Article
C2 - 22354543
AN - SCOPUS:84861726534
VL - 59
SP - 417
EP - 422
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
SN - 1545-5009
IS - 3
ER -